{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:20:39Z","timestamp":1794306039105,"version":"4.9.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Innovation Foundation for Doctor Dissertation of Northwestern Polytechnical University","award":["ZX2025005"],"award-info":[{"award-number":["ZX2025005"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82374074"],"award-info":[{"award-number":["82374074"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173682"],"award-info":[{"award-number":["82173682"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2022-I2M-1-015"],"award-info":[{"award-number":["2022-I2M-1-015"]}]},{"name":"Shenzhen Science and Technology Program","award":["JCYJ20240813150807010"],"award-info":[{"award-number":["JCYJ20240813150807010"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Metabolic reprogramming, particularly upregulated\n                      <jats:italic>de novo<\/jats:italic>\n                      pyrimidine biosynthesis, drives cancer progression and immune evasion. Dihydroorotate dehydrogenase (DHODH), a key enzyme in this pathway, is a promising therapeutic target, but its inhibitors often face resistance in immune-refractory melanoma, linked to low basal stimulator of interferon genes (STING) expression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To overcome this limitation, we designed H62, a tumor-selective prodrug conjugating the DHODH inhibitor EA6 with the STING agonist MSA-2 via a cathepsin B-cleavable linker. Mechanistic studies evaluated mitochondrial disruption, pyroptosis (caspase-3\/GSDME), and STING-mediated interferon signaling, alongside natural killer (NK) cell recruitment. Efficacy was tested in multiple melanoma models, including standard and neoadjuvant settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>H62 synergistically induced mitochondrial dysfunction and pyroptosis while activating STING\/type I interferon responses, enhancing NK cell cytotoxicity. In melanoma models, it significantly suppressed tumor growth, reduced postoperative recurrence, and improved survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This dual-targeting strategy overcomes DHODH inhibitor resistance by coupling metabolic interference with innate immune activation, offering translational potential for melanoma and other treatment-resistant cancers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03566-6","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T16:19:54Z","timestamp":1763137194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["An immunometabolic prodrug strategy overcomes DHODH inhibitor resistance in refractory melanoma"],"prefix":"10.1186","volume":"44","author":[{"given":"Yongrui","family":"Hai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renming","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyan","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiquan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junke","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaofei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"3566_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.semcancer.2025.03.003","volume":"112","author":"H Wang","year":"2025","unstructured":"Wang H, Xu F, Wang C. Metabolic reprogramming of tumor microenviroment by engineered bacteria. Semin Cancer Biol. 2025;112:58\u201370.","journal-title":"Semin Cancer Biol"},{"key":"3566_CR2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41568-024-00786-4","volume":"25","author":"P Altea-Manzano","year":"2025","unstructured":"Altea-Manzano P, Decker-Farrell A, Janowitz T, Erez A. Metabolic interplays between the tumour and the host shape the tumour macroenvironment. Nat Rev Cancer. 2025;25:274\u201392.","journal-title":"Nat Rev Cancer"},{"key":"3566_CR3","doi-asserted-by":"publisher","unstructured":"Ramesh V, Demirdizen M, Pinna L, Doktor TK, Siddiqui MA, Ceppi P. Pan-cancer analysis of pyrimidine metabolism reveals signaling pathways connections with chemoresistance role. bioRxiv. 2024. https:\/\/doi.org\/10.1101\/2023.12.06.570388.","DOI":"10.1101\/2023.12.06.570388"},{"key":"3566_CR4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41568-023-00557-7","volume":"23","author":"NJ Mullen","year":"2023","unstructured":"Mullen NJ, Singh PK. Nucleotide metabolism: a pan-cancer metabolic dependency. Nat Rev Cancer. 2023;23:275\u201394.","journal-title":"Nat Rev Cancer"},{"key":"3566_CR5","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41586-021-03539-7","volume":"593","author":"C Mao","year":"2021","unstructured":"Mao C, Liu X, Zhang Y, Lei G, Yan Y, Lee H, et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature. 2021;593:586\u201390.","journal-title":"Nature"},{"key":"3566_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s40170-021-00250-z","volume":"9","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Tao L, Zhou X, Zuo Z, Gong J, Liu X, et al. DHODH and cancer: promising prospects to be explored. Cancer Metab. 2021;9:22.","journal-title":"Cancer Metab"},{"key":"3566_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107115","volume":"202","author":"Y Hai","year":"2024","unstructured":"Hai Y, Fan R, Zhao T, Lin R, Zhuang J, Deng A, et al. A novel mitochondria-targeting DHODH inhibitor induces robust ferroptosis and alleviates immune suppression. Pharmacol Res. 2024;202:107115.","journal-title":"Pharmacol Res"},{"key":"3566_CR8","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/s41423-023-01014-z","volume":"20","author":"G Kim","year":"2023","unstructured":"Kim G, Shin HM, Kim HR. Pyrimidine nucleotide starvation induces a decrease in the number of effector T cells but not memory T cells. Cell Mol Immunol. 2023;20:859\u201360.","journal-title":"Cell Mol Immunol"},{"key":"3566_CR9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI158661","volume":"132","author":"SH Colligan","year":"2022","unstructured":"Colligan SH, Amitrano AM, Zollo RA, Peresie J, Kramer ED, Morreale B, et al. Inhibiting the biogenesis of myeloid-derived suppressor cells enhances immunotherapy efficacy against mammary tumor progression. J Clin Invest. 2022;132:e158661.","journal-title":"J Clin Invest"},{"key":"3566_CR10","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.173646","volume":"9","author":"OA Elgamal","year":"2024","unstructured":"Elgamal OA, Fobare S, Vibhute S, Mehmood A, Vroom DC, Johnson ML, et al. Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia. JCI Insight. 2024;9:e173646.","journal-title":"JCI Insight"},{"key":"3566_CR11","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.cmet.2019.02.001","volume":"29","author":"CJ Halbrook","year":"2019","unstructured":"Halbrook CJ, Pontious C, Kovalenko I, Lapienyte L, Dreyer S, Lee HJ, et al. Macrophage-Released pyrimidines inhibit gemcitabine therapy in pancreatic cancer. Cell Metab. 2019;29:1390\u2013e96.","journal-title":"Cell Metab"},{"key":"3566_CR12","doi-asserted-by":"publisher","unstructured":"Hai Y, Lin R, Liao W, Fu S, Fan R, Ding G, et al. Dihydroorotate dehydrogenase inhibition activates STING pathway and pyroptosis to enhance NK cell-dependent tumor immunotherapy. Mol Biomed. 2025. https:\/\/doi.org\/10.1186\/s43556-025-00339-7.","DOI":"10.1186\/s43556-025-00339-7"},{"issue":"1","key":"3566_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-01025-9","volume":"21","author":"A Amos","year":"2023","unstructured":"Amos A, Amos A, Wu L, Xia H. The warburg effect modulates DHODH role in ferroptosis: a review. Cell Commun Signal. 2023;21(1):100.","journal-title":"Cell Commun Signal"},{"key":"3566_CR14","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41568-021-00378-6","volume":"21","author":"I Mart\u00ednez-Reyes","year":"2021","unstructured":"Mart\u00ednez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21:669\u201380.","journal-title":"Nat Rev Cancer"},{"key":"3566_CR15","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","volume":"3","author":"N 15 Samson","year":"2022","unstructured":"15 Samson N, Ablasser A. The cGAS-STING pathway and cancer. Nat Cancer. 2022;3:1452\u201363.","journal-title":"Nat Cancer"},{"key":"3566_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","volume":"10","author":"J Kwon","year":"2020","unstructured":"Kwon J, Bakhoum SF. The cytosolic DNA-sensing cGAS-STING pathway in cancer. Cancer Discov. 2020;10:26\u201339.","journal-title":"Cancer Discov"},{"key":"3566_CR17","doi-asserted-by":"crossref","unstructured":"Xian H, Watari K, Sanchez-Lopez E, Offenberger J, Onyuru J, Sampath H et al. Oxidized DNA fragments exit mitochondria via mPTP- and VDAC-dependent channels to activate NLRP3 inflammasome and interferon signaling. Immunity. 2022;55:1370-85.e8.","DOI":"10.1016\/j.immuni.2022.06.007"},{"key":"3566_CR18","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41556-023-01185-x","volume":"25","author":"L Zhang","year":"2023","unstructured":"Zhang L, Jiang C, Zhong Y, Sun K, Jing H, Song J, et al. STING is a cell-intrinsic metabolic checkpoint restricting aerobic glycolysis by targeting HK2. Nat Cell Biol. 2023;25:1208\u201322.","journal-title":"Nat Cell Biol"},{"key":"3566_CR19","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1084\/jem.20101159","volume":"208","author":"MB Fuertes","year":"2011","unstructured":"Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, et al. Host type I IFN signals are required for antitumor CD8\u2009+\u2009T cell responses through CD8{alpha}+ dendritic cells. J Exp Med. 2011;208:2005\u201316.","journal-title":"J Exp Med"},{"key":"3566_CR20","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1084\/jem.20101158","volume":"208","author":"MS Diamond","year":"2011","unstructured":"Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011;208:1989\u20132003.","journal-title":"J Exp Med"},{"key":"3566_CR21","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.actbio.2024.02.003","volume":"177","author":"P Wang","year":"2024","unstructured":"Wang P, Wang Y, Li H, Wang M, Wang Y, Wang X, et al. A homologous-targeting cGAS-STING agonist multimodally activates dendritic cells for enhanced cancer immunotherapy. Acta Biomater. 2024;177:400\u201313.","journal-title":"Acta Biomater"},{"key":"3566_CR22","doi-asserted-by":"crossref","unstructured":"Marcus A, Mao AJ, Lensink-Vasan M, Wang L, Vance RE, Raulet DH. Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response. Immunity. 2018;49:754\u201363.e4.","DOI":"10.1016\/j.immuni.2018.09.016"},{"key":"3566_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113108","volume":"42","author":"L Lu","year":"2023","unstructured":"Lu L, Yang C, Zhou X, Wu L, Hong X, Li W, et al. Sting signaling promotes NK cell antitumor immunity and maintains a reservoir of TCF-1(+) NK cells. Cell Rep. 2023;42:113108.","journal-title":"Cell Rep"},{"key":"3566_CR24","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1158\/2326-6066.CIR-22-0017","volume":"10","author":"EH Knelson","year":"2022","unstructured":"Knelson EH, Ivanova EV, Tarannum M, Campisi M, Lizotte PH, Booker MA, et al. Activation of tumor-cell STING primes NK-cell therapy. Cancer Immunol Res. 2022;10:947\u201361.","journal-title":"Cancer Immunol Res"},{"key":"3566_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215981","volume":"552","author":"NJ Mullen","year":"2023","unstructured":"Mullen NJ, Thakur R, Shukla SK, Chaika NV, Kollala SS, Wang D, et al. ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer. Cancer Lett. 2023;552:215981.","journal-title":"Cancer Lett"},{"key":"3566_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116329","volume":"269","author":"F Liu","year":"2024","unstructured":"Liu F, Zhou T, Zhang S, Li Y, Chen Y, Miao Z, et al. Cathepsin b: the dawn of tumor therapy. Eur J Med Chem. 2024;269:116329.","journal-title":"Eur J Med Chem"},{"key":"3566_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114529","volume":"161","author":"C Yang","year":"2023","unstructured":"Yang C, Wang ZQ, Zhang ZC, Lou G, Jin WL. CBL0137 activates ROS\/BAX signaling to promote caspase-3\/GSDME-dependent pyroptosis in ovarian cancer cells. Biomed Pharmacother. 2023;161:114529.","journal-title":"Biomed Pharmacother"},{"key":"3566_CR28","doi-asserted-by":"publisher","first-page":"8159","DOI":"10.1111\/jcmm.16574","volume":"25","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Zhang H, Li D, Zhou X, Qin Q, Zhang Q. Caspase-3-mediated GSDME induced pyroptosis in breast cancer cells through the ROS\/JNK signalling pathway. J Cell Mol Med. 2021;25:8159\u201368.","journal-title":"J Cell Mol Med"},{"key":"3566_CR29","first-page":"4310","volume":"12","author":"P Broz","year":"2025","unstructured":"Broz P. Pyroptosis: molecular mechanisms and roles in disease. Cell Res. 2025;12:4310\u201329.","journal-title":"Cell Res"},{"key":"3566_CR30","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.apsb.2024.11.011","volume":"15","author":"Z Li","year":"2025","unstructured":"Li Z, Xi Z, Fan C, Xi X, Zhou Y, Zhao M, et al. Nanomaterials evoke pyroptosis boosting cancer immunotherapy. Acta Pharm Sin B. 2025;15:852\u201375.","journal-title":"Acta Pharm Sin B"},{"key":"3566_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05304-6","volume":"22","author":"X Li","year":"2024","unstructured":"Li X, Ma S, Wang Q, Li Y, Ji X, Liu J, et al. A new integrative analysis of histopathology and single cell RNA-seq reveals the CCL5 mediated T and NK cell interaction with vascular cells in idiopathic pulmonary arterial hypertension. J Transl Med. 2024;22:502.","journal-title":"J Transl Med"},{"key":"3566_CR32","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41586-023-06073-w","volume":"618","author":"ZC Nwosu","year":"2023","unstructured":"Nwosu ZC, Ward MH, Sajjakulnukit P, Poudel P, Ragulan C, Kasperek S, et al. Uridine-derived ribose fuels glucose-restricted pancreatic cancer. Nature. 2023;618:151\u20138.","journal-title":"Nature"},{"key":"3566_CR33","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.ccell.2024.05.006","volume":"42","author":"Y Li","year":"2024","unstructured":"Li Y, Huang M, Wang M, Wang Y, Deng P, Li C, et al. Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite. Cancer Cell. 2024;42:985\u2013e100218.","journal-title":"Cancer Cell"},{"key":"3566_CR34","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41590-023-01462-9","volume":"24","author":"X Zheng","year":"2023","unstructured":"Zheng X, Hou Z, Qian Y, Zhang Y, Cui Q, Wang X, et al. Tumors evade immune cytotoxicity by altering the surface topology of NK cells. Nat Immunol. 2023;24:802\u201313.","journal-title":"Nat Immunol"},{"key":"3566_CR35","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41586-022-05254-3","volume":"610","author":"S Li","year":"2022","unstructured":"Li S, Mirlekar B, Johnson BM, Brickey WJ, Wrobel JA, Yang N, et al. STING-induced regulatory B cells compromise NK function in cancer immunity. Nature. 2022;610:373\u201380.","journal-title":"Nature"},{"key":"3566_CR36","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2054105","volume":"11","author":"Y Da","year":"2022","unstructured":"Da Y, Liu Y, Hu Y, Liu W, Ma J, Lu N, et al. STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer. Oncoimmunology. 2022;11:2054105.","journal-title":"Oncoimmunology"},{"key":"3566_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26020515","volume":"26","author":"S Fanijavadi","year":"2025","unstructured":"Fanijavadi S, Thomassen M, Jensen LH. Targeting triple NK cell suppression mechanisms: a comprehensive review of biomarkers in pancreatic cancer therapy. Int J Mol Sci. 2025;26:515.","journal-title":"Int J Mol Sci"},{"key":"3566_CR38","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41586-020-2071-9","volume":"579","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Zhang Y, Xia S, Kong Q, Li S, Liu X, et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature. 2020;579:415\u201320.","journal-title":"Nature"},{"key":"3566_CR39","doi-asserted-by":"publisher","first-page":"15918","DOI":"10.1021\/acsnano.3c03980","volume":"17","author":"S Prakash","year":"2023","unstructured":"Prakash S, Kumbhojkar N, Lu A, Kapate N, Suja VC, Park KS, et al. Polymer micropatches as natural killer cell engagers for tumor therapy. ACS Nano. 2023;17:15918\u201330.","journal-title":"ACS Nano"},{"key":"3566_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002852","volume":"9","author":"T Nakamura","year":"2021","unstructured":"Nakamura T, Sato T, Endo R, Sasaki S, Takahashi N, Sato Y, et al. STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation. J Immunother Cancer. 2021;9:e002852.","journal-title":"J Immunother Cancer"},{"key":"3566_CR41","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1016\/j.ymthe.2024.01.027","volume":"32","author":"K Wang","year":"2024","unstructured":"Wang K, Wang L, Wang Y, Xiao L, Wei J, Hu Y, et al. Reprogramming natural killer cells for cancer therapy. Mol Ther. 2024;32:2835\u201355.","journal-title":"Mol Ther"},{"key":"3566_CR42","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jconrel.2015.08.026","volume":"216","author":"T Nakamura","year":"2015","unstructured":"Nakamura T, Miyabe H, Hyodo M, Sato Y, Hayakawa Y, Harashima H. Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma. J Control Release. 2015;216:149\u201357.","journal-title":"J Control Release"},{"key":"3566_CR43","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","volume":"19","author":"DJ Propper","year":"2022","unstructured":"Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022;19:237\u201353.","journal-title":"Nat Rev Clin Oncol"},{"key":"3566_CR44","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.soc.2020.03.001","volume":"29","author":"MC Lowe","year":"2020","unstructured":"Lowe MC, Kudchadkar RR. Neoadjuvant therapy for melanoma. Surg Oncol Clin N Am. 2020;29:445\u201353.","journal-title":"Surg Oncol Clin N Am"},{"key":"3566_CR45","doi-asserted-by":"publisher","first-page":"e378","DOI":"10.1016\/S1470-2045(19)30332-8","volume":"20","author":"RN Amaria","year":"2019","unstructured":"Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, et al. Neoadjuvant systemic therapy in melanoma: recommendations of the international neoadjuvant melanoma consortium. Lancet Oncol. 2019;20:e378\u201389.","journal-title":"Lancet Oncol"},{"key":"3566_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2024.102127","volume":"56","author":"AD Therien","year":"2024","unstructured":"Therien AD, Chime-Eze CM, Rhodin KE, Beasley GM. Neoadjuvant therapy for melanoma: past, present, and future. Surg Oncol. 2024;56:102127.","journal-title":"Surg Oncol"},{"key":"3566_CR47","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw5473","author":"B Faubert","year":"2020","unstructured":"Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020. https:\/\/doi.org\/10.1126\/science.aaw5473.","journal-title":"Science"},{"key":"3566_CR48","doi-asserted-by":"crossref","unstructured":"Madak JT, Bankhead A 3rd, Cuthbertson CR, Showalter HD, Neamati N. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer. Pharmacol Ther. 2019;195:111\u201331.","DOI":"10.1016\/j.pharmthera.2018.10.012"},{"key":"3566_CR49","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/med.22079","volume":"45","author":"J Li","year":"2025","unstructured":"Li J, Wang X, Zhang H, Hu X, Peng X, Jiang W, et al. Fenamates: forgotten treasure for cancer treatment and prevention: mechanisms of action, structural modification, and bright future. Med Res Rev. 2025;45:164\u2013213.","journal-title":"Med Res Rev"},{"key":"3566_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215837","volume":"549","author":"D He","year":"2022","unstructured":"He D, Chen M, Chang L, Gu J, Liu F, Gao X, et al. De novo pyrimidine synthesis fuels glycolysis and confers chemoresistance in gastric cancer. Cancer Lett. 2022;549:215837.","journal-title":"Cancer Lett"},{"key":"3566_CR51","doi-asserted-by":"publisher","first-page":"87292","DOI":"10.7554\/eLife.87292","volume":"12","author":"NJ Mullen","year":"2024","unstructured":"Mullen NJ, Shukla SK, Thakur R, Kollala SS, Wang D, Chaika N, et al. DHODH Inhibition enhances the efficacy of immune checkpoint Blockade by increasing cancer cell antigen presentation. Elife. 2024;12:87292.","journal-title":"Elife"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03566-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03566-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03566-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T01:03:56Z","timestamp":1763168636000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03566-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3566"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03566-6","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The tumor and adjacent nontumor tissues used in this research were obtained written informed consent from the patients in the Fudan University Shanghai Cancer Center. All samples in this research were all collected at Fudan University Shanghai Cancer Center and stored at -80\u00a0\u00b0C or 4% paraformaldehyde. These experimental protocols were approved by the Ethics Committee of Fudan University Shanghai Cancer Center (2407-ZZK-123).All procedures conducted on animals complied with the ARRIVE guidelines (EU Directive 2010\/63\/EU for animal experiments). All the experiments involving animals were performed according to protocols approved by the Institutional Animal Care and Use Committee of Northwestern Polytechnical University (202301196).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"306"}}